Modeled global cases of the birth defect syndrome caused by rubella have fallen by roughly 73 percent since 2012, from an estimated 101,381 a year to 26,859, according to a CDC analysis published in the Morbidity and Mortality Weekly Report. The remaining burden is not spread evenly. In 2024, the African Region accounted for 89 percent of estimated cases worldwide.
That concentration is what makes the finding useful rather than merely encouraging. Rubella is usually a mild febrile rash illness, and a quarter to half of infections are asymptomatic. Its danger is specific: infection during early pregnancy can cause miscarriage, fetal death, stillbirth, or a cluster of birth defects that includes deafness, cataracts, heart defects, and developmental delay.
For American readers, that turns a global surveillance report into a travel question. Anyone who is pregnant, planning a pregnancy, or traveling with a partner who is, now has a clearer map of where the risk actually sits.
Where the Vaccine Has and Has Not Arrived
By 2024, 179 of 194 countries had introduced rubella-containing vaccine into routine immunization, up from 132 in 2012. Global first-dose coverage among infants aged 12 to 23 months rose from 39 percent to 73 percent over the same period.
Fifteen countries still do not include the rubella vaccine in their routine schedules, and roughly 21 million infants live in them, about 16 percent of the global birth cohort. According to the CDC report, those countries are concentrated in low-income and conflict-affected settings: Afghanistan, Central African Republic, Chad, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Ethiopia, Gabon, Guinea, Liberia, Madagascar, Niger, Nigeria, Somalia, and South Sudan.
Reported rubella cases fell 80 percent between 2012 and 2022, then rose again to 31,593 in 2024. That rebound was driven by transmission in Chad and Nigeria, which had not introduced the vaccine, and in South Africa during its vaccine rollout. Nigeria and the Democratic Republic of the Congo began introducing the vaccine in 2025 and 2026, which researchers expect to substantially reduce the unvaccinated birth cohort. A separate CDC modeling analysis projected that introducing it across the 19 remaining countries could avert more than 986,000 birth defect cases over three decades.
A total of 117 countries have now been verified as having eliminated endemic rubella transmission, up from 84 in 2019. The authors noted that "no country that has achieved rubella elimination has experienced reestablished endemic transmission."
Coverage varies sharply by income group. In 2024, rubella vaccination coverage was 30 percent across low-income countries, compared with 79 percent in lower-middle-income countries, 87 percent in upper-middle-income countries, and 93 percent in high-income countries. Among countries that have actually introduced the vaccine, coverage in low-income settings reached 82 percent, which suggests the dominant barrier is program introduction rather than uptake once a program exists.
The Americas Are Not Insulated
The Region of the Americas was the first to eliminate rubella in 2015, and all 35 countries have maintained that status. Zero rubella cases were reported in the region in 2024. That does not mean zero risk.
CDC documented a case of congenital rubella syndrome in Florida during 2025, described in a separate Notes from the Field report. A hospital reported a six-day-old infant with microcephaly, cataracts, a congenital heart defect, and hearing deficits. The mother, a South African citizen living in Florida, had visited her home country and was presumably never vaccinated because South Africa did not add the rubella vaccine to its routine childhood schedule until 2024. Genotyping identified rubella virus genotype 2B, with sequences closely related to strains circulating in South Africa in 2024, during which an outbreak of roughly 10,000 cases occurred. Investigators concluded the mother was most likely infected during the first three weeks of pregnancy.
That single case illustrates the mechanism the CDC report describes in one line: as long as rubella circulates anywhere, the risk of importation persists everywhere, including in countries that have eliminated it. Rubella and congenital rubella syndrome were declared eliminated in the United States in 2004, but elimination refers to transmission, not a wall.
There is a second reason a single case draws attention. Infants born with congenital rubella syndrome are considered infectious until age 12 months, or until two negative rubella PCR results from samples collected a month apart. In the Florida case, contact tracing identified 22 hospital staff members with close contact, all of whom had evidence of immunity.
A Domestic Policy Question Now Sits Alongside the Global One
In the United States, rubella protection is delivered almost entirely through the combined measles, mumps, and rubella vaccine. On August 10, President Donald Trump signed an executive order on childhood vaccines recommending that MMR be administered as three separate single-disease shots once such products are domestically available, and that childhood immunizations be given at separate medical visits where feasible.
Standalone measles, mumps, and rubella vaccines are not currently licensed or sold in the United States. Separating them would require manufacturers to develop and produce three products, and no data show a benefit from spacing the doses. The CDC childhood schedule has not changed, and public health organizations have said additional visits could raise costs and increase the chance of missed doses. Both the World Health Organization and the CDC note that a single dose of the rubella-containing vaccine provides lifelong protection.
Parents do not need to change anything today. MMR remains available on the existing schedule.
Practical Guidance Before Travel or Pregnancy
Anyone planning a pregnancy can ask a clinician to check rubella immunity with a simple blood test. CDC recommends that women of reproductive age without documentation of vaccination or other evidence of immunity be offered a rubella-containing vaccine before pregnancy, not during it, because MMR is a live vaccine. Adults who never received MMR and have no documented immunity should discuss catch-up vaccination.
Travelers heading to countries with ongoing rubella transmission, particularly in sub-Saharan Africa and parts of the Eastern Mediterranean region, should confirm their own status and their children's records well before departure. Fever with a rash appearing within three weeks of returning warrants a call to a clinician with the travel history mentioned up front, since the incubation period runs about 12 to 23 days. The stakes of that call are visible in the United States right now, where measles elimination status is under review.
Uncertainties remain. Reported case counts depend on surveillance quality that varies widely by country; some systems have not recovered to pre-pandemic performance, and the birth defect estimates come from a model that relies on incomplete seroprevalence data. The report states those limitations directly. The effects of the Nigeria and Congo rollouts should begin appearing in future reporting cycles.
Key Questions Answered
What did the CDC report find? Global rubella vaccine coverage among infants rose from 39 percent in 2012 to 73 percent in 2024, and modeled cases of congenital rubella syndrome fell by about 73 percent over the same period.
Why does rubella matter if it is usually mild? Infection during early pregnancy can cause miscarriage, fetal death, stillbirth, or birth defects, including deafness, cataracts, heart defects, and developmental delay.
Where is the remaining risk concentrated? The African Region accounted for 89 percent of estimated congenital rubella syndrome cases in 2024. Fifteen countries still do not include the rubella vaccine in their routine immunization schedule.
Can rubella still appear in the United States? Yes, through importation. CDC documented a congenital rubella syndrome case in Florida in 2025, with a viral strain related to those circulating in South Africa.
Does the August executive order change what parents should do? Not at present. Standalone measles, mumps, and rubella vaccines are not licensed or available in the United States, and the CDC childhood schedule has not changed.
What should someone planning a pregnancy do? Ask a clinician to check rubella immunity with a blood test. Vaccination is recommended before conception, since MMR is a live vaccine and is not given during pregnancy.
How reliable are these numbers? Reported counts depend on surveillance quality that varies by country, and the birth defect figures are modeled estimates rather than direct counts. The report states those limitations directly.
